



STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON 31ST MARCH, 2018				
Sr. No.	Particulars	31-Mar-2018 (12 Months) (Audited)	31-Mar-2017 (12 Months) (Audited)	
I	<b>Revenue</b>			
	Revenue from Operations	6,061.61	11671.36	
	Other Income	213.31	223.69	
	<b>Total Revenue (I+II)</b>	<b>6,274.92</b>	<b>11,895.05</b>	
II	<b>Expenses</b>			
	(a) Cost of Materials Consumed	1,848.03	3,536.67	
	(b) Purchase of traded goods	909.54	2,040.98	
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	180.36	(192.88)	
	(d) Excise Duty	81.00	663.25	
	(e) Employee benefits expense	1,698.31	1,724.28	
	(f) Finance Costs	795.61	1,872.00	
	(g) Depreciation and amortisation expense	1,128.16	1,025.35	
	(h) Other expenses	1,861.87	1,622.01	
	<b>Total expenses</b>	<b>8,502.88</b>	<b>12,291.66</b>	
III	<b>Profit/(Loss) before Exceptional Items and Taxes</b>	(2,227.96)	(396.61)	
IV	<b>Exceptional Items (Net)</b>	(223.50)	(413.65)	
V	<b>Non Controlling Interest</b>	(178.90)	104.73	
VI	<b>Profit/(Loss) before Tax</b>	<b>(1,825.56)</b>	<b>(705.53)</b>	
Vii	Tax Expenses	(103.98)	150.61	
Viii	<b>Profit/(Loss) for the period</b>	<b>(1,721.58)</b>	<b>(554.92)</b>	
IX	Other Comprehensive Income	44.20	(11.51)	
X	<b>Total Comprehensive Income</b>	<b>(1,765.78)</b>	<b>(566.43)</b>	
XI	Paid up Equity Share Capital ( face value Rs.10/- per share)	2,814.00	2,204.00	
	<b>Earnings Per Share of Rs 10/-each (not annualised)</b>			
	(a) Basic	(6.71)	(2.57)	
	(b) Diluted	(6.71)	(2.57)	

LYKA LABS LIMITED				
CONSOLIDATED STATEMENT OF ASSETS AND LIABILITY FOR THE YEAR ENDED ON 31ST MARCH, 2018				
(Rs.In lakhs)				
Particulars			As at 31st March, 2018	As at 31st March, 2017
I		<b>ASSETS</b>		
1		<b>Non-current assets</b>		
	(a)	Property, Plant and Equipment	7,735.23	8,238.24
	(b)	Capital Work- In- Progress	1,666.25	1,669.63
	(c)	Intangible assets	4,410.05	5,051.26
	(d)	Intangible assets under development	1,121.40	753.64
			14,932.93	15,712.77
	(e)	<b>Financial Assets</b>		
	(i)	Investments	2,272.78	26.12
	(ii)	Other Financial Assets	2,384.01	2,481.27
	(iii)	Other Non-current Tax Expenses	380.92	336.65
	(iii)	Other Non-current Assets Deferred tax	395.23	290.22
			<b>20,365.87</b>	<b>18,847.03</b>
2		<b>Current Assets</b>		
	(a)	Inventories	1,119.69	1,324.07
	(b)	<b>Financial Assets</b>		
	(i)	Current Investments	0.06	-
	(ii)	Trade Receivables	2,049.61	2,981.36
	(iii)	Cash and Cash Equivalents	242.87	512.19
	(iv)	Loan	808.29	726.24
	(v)	Other Financial Assets	252.39	236.40
	(c)	Other Current Assets	1,338.03	549.08
			5,810.94	6,329.34
		<b>TOTAL</b>	<b>26,176.81</b>	<b>25,176.37</b>
II		<b>EQUITY AND LIABILITIES</b>		
1		<b>Equity</b>		
	(a)	Equity Share Capital	2,814.00	2,204.00
	(b)	Other Equity	5,155.07	1,983.13
			7,969.07	4,187.13
		Non Controlling Interest	104.48	286.57
2		<b>Liabilities</b>		
		<b>Non-Current Liabilities</b>		
		<b>Financial Liabilities</b>		
	(a)	Borrowings	493.16	3,577.23
	(b)	Other Financial Liabilities	66.88	154.11
	(c)	Provisions	363.25	426.54
			1,027.77	4,444.45
		<b>Current Liabilities</b>		
		<b>Financial Liabilities</b>		
	(a) (i)	Borrowings	4,517.67	5,023.06
	(ii)	Trade Payables	1,858.63	4,680.50
	(iii)	Other Financial Liability	10,332.12	6,542.50
	(b)	Other Current Liabilities	471.55	298.73
	(c)	Provisions	17,179.97	16,544.79
		<b>TOTAL</b>	<b>26,176.81</b>	<b>25,176.37</b>
			FOR LYKA LABS LIMITED	
			 N.I.GANDHI CMD DIN : 00021530	



## Notes :

1. The above audited financial results as reviewed by the Audit Committee, have been approved and taken on record at the meeting of the Board of Directors held on 29<sup>th</sup> May, 2018.
2. The figures for the last quarter ended 31<sup>st</sup> March, 2018 are the balancing figures between audited figures in respect of the year ended 31<sup>st</sup> March, 2018 and published year to date figures upto 31<sup>st</sup> December, 2017.
3. The Statutory Auditors of the Holding Company have carried out the audit of Consolidated basis of the financial results for the year ended 31<sup>st</sup> March, 2018.
4. Consolidated Audited financial results for the year ended 31<sup>st</sup> March, 2018 includes audited financials of subsidiaries, Lyka BDR International Limited., Lyka Healthcare Limited., and Lyka Exports., for the year ended 31<sup>st</sup> March, 2018.
5. The Group has adopted Indian Accounting Standards ("Ind AS") notified by the Ministry of Corporate Affairs w.e.f. 1<sup>st</sup> April, 2017.

6. **Interest On Borrowings:**

The Holding Company has applied to two of its banks for settlement of principal / interest amount. The management has accordingly reversed interest on term loan provided for the period from April 2017 to September 2017 amounting to Rs 469.92 Lakhs and has not provided interest on term loan from said two banks for the period from October 2017 to March 2018 amounting to Rs 471.64 Lakhs, aggregating to Rs. 941.56 Lakhs.

Further the Holding Company has reversed interest expenses for earlier years for the period from February 2016 to March 2017 amounting to Rs 344.35 Lakhs. There is also no provision for penal interest on term loan from two banks and working capital limit from one bank amounting to Rs 80.04 Lakhs.

7. **Inventories:**

Inventories include slow/non-moving raw material and packing materials procured during the earlier years amounting to 174.06 lakhs as on 31<sup>st</sup> March 2018, which are valued at cost. The Company is evaluating to utilize/realise the same.

8. **Pledged shares of a Director encashed by a Lender:**

The Holding Company has received claims from a Director aggregating to Rs. 128.25 lakhs being the value of 225,000 equity shares of Lyka Labs Limited pledged as security for finance supposed to have been provided by a Lender to the Holding Company. These pledged shares were allegedly invoked by Lender. Further, the said Director has claimed the interest on the same, post invocation of the pledged shares.





Pending receipt of documentary evidence to substantiate the above claims, the Holding Company has debited Lender with Rs. 128.25 lakhs. However, the said Lender has not confirmed the same for which no provision has been made in the books. The Holding Company is in the process of resolving the counter claims of both the parties.

**9. Scheme of Arrangements:-**

- (a) The Board of Directors at their meeting held on 10<sup>th</sup> March, 2016 resolved to merge Company's Subsidiary i.e. Lyka Exports Limited with it, effective from 1<sup>st</sup> April, 2015 ("Appointed Date") under the provisions of sections 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30<sup>th</sup> November, 2015. Since then the "appointed date" of the said merger of Lyka Exports Limited is postponed to 1<sup>st</sup> April, 2017 by The Board of Directors at their meeting held on 30<sup>th</sup> August, 2017.
- (b) The Board of Directors at their meeting held on 29<sup>th</sup> May 2017, resolved to merge Company's subsidiary Lyka Healthcare Limited with it effective from 1<sup>st</sup> April, 2017 ("Appointed Date") under the provisions of sections 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30<sup>th</sup> November, 2015.

The National Company Law Tribunal (NCLT), Ahmedabad approved the application vide its order dated 6<sup>th</sup> February 2018 and ordered to call Equity/ Preference Shareholders and Secured/ Unsecured Creditors meeting on 27<sup>th</sup> March, 2018 for approving the arrangement

The Equity / Preference Shareholders at the meetings convened, approved the merger. The Unsecured Creditors at their meeting also approved the merger. However, the meeting of Secured Creditors could not be proceeded, due of lack of quorum. Accordingly, the Company filed an interlocutory Application on 13<sup>th</sup> April 2018, before NCLT seeking directions for re-convening / conducting a fresh meeting of the Secured Creditors. Pursuant to Interlocutory Application, NCLT passed an order dated 9<sup>th</sup> May, 2018 directing the Company for reconvening meeting of Secured Creditors on 2<sup>nd</sup> July, 2018.

**10. Capital Expenditure:**

The Company has reviewed its portfolio of products under development and applied research. Accordingly, a sum of Rs. 976.53 Lakhs for the year ended including finance cost is carried forward as "Capital Work-in-Progress - Intangibles" to be recognized as "Self-Generated Intangible Assets" upon successful development and commercial viability of the respective products. However, the carrying cost of those product's which do not confirm to the test of commercial viability are charged to the Statement of Profit and Loss.



**11. Exceptional Items:**

Exceptional items consist of :

Sr. No.	Particulars	(Rs. In lakhs)
		Year ended 31st March, 2018
1.	Interest written back / off of previous years (Net)	(248.59)
2.	Irrecoverable claim/advances written off	(76.39)
3.	Sales Tax paid under Amnesty Scheme	81.61
4.	Short Provision of Expenses in earlier years	19.86
	<b>TOTAL</b>	<b>(223.50)</b>

**Note:** Figures in brackets denote items of income nature.

12. The reconciliation between results as reported under erstwhile Indian GAAP and Ind AS is summarised as below:-

**(i) Profit Reconciliation:-**

(Rs. in Lakhs)

Sr. No.	Particulars	Year ended 31st March, 2017
	Net Profit/(Loss) as per Indian GAAP	(467.57)
a.	Fair Value of Financial Assets/Financial Liabilities	26.59
b.	Restatement of Fair Value of Investment	4.37
c.	Incremental Depreciation on Fair Value as Deemed Cost on initial recognition on selective basis	(123.66)
d.	Remeasurement of Post Employment Benefit Obligations	10.93
e.	Expected Credit Loss on Financial Assets	(53.72)
f.	Deferred Tax impact on above	47.56
	<b>Net Profit / (Loss) before OCI as per Ind AS</b>	<b>(555.1)</b>
g.	Other comprehensive income (OCI)	(10.93)
	<b>Total Comprehensive income under Ind AS</b>	<b>(566.43)</b>

**(ii) Equity Reconciliation:-**

Sr. No.	Particulars	Year ended 31st March, 2017	On 1st April, 2016
	<b>Total equity (shareholder's funds) as per previous GAAP</b>	<b>3920.39</b>	<b>4524.06</b>
	<b>Adjustments:</b>		
a.	Reclassification of Cumulative Redeemable Preference Shares	(108.57)	(108.57)
b.	Fair Value of Financial Assets/Liabilities	(276.20)	(302.78)
c.	Fair Value of Investments	8.37	2.84
d.	Expected Credit Loss on Financial Assets	(221.37)	(167.66)
e.	Prior Period Adjustments	(1858.13)	(1858.13)
f.	Opening Balance of Revaluation Reserve transferred	2853.45	2853.45
g.	Foreign Currency Monetary Translation Difference Reserve transferred	(138.24)	(138.24)
h.	Incremental Depreciation on Fair Value as Deemed Cost on initial recognition on selective basis	(123.66)	--





i.	Deferred Tax impact on above	131.09	84.69
	<b>Total adjustments</b>		
	<b>Total equity as per Ind AS</b>	<b>4187.13</b>	<b>4889.66</b>

13. The format for quarterly results as prescribed in SEBI's Circular CIR/CFB/CMD/15/2015 dt. Nov 30, 2015 has been modified to comply with the requirements of SEBI's circular dt. Jul 5, 2016.
14. Post the applicability of Goods and Service Tax (GST) w.e.f. July 1, 2017, revenue from operations is disclosed net of GST, accordingly, the revenue from operations and other expenses for the quarter/ year ended on March 31, 2018 are not comparable with the corresponding previous period figures.
15. The Group business activities as reviewed by the Board of Directors, falls within a single operating segment viz. "Pharmaceuticals" as per IndAS 108 Operating Segments and hence segment disclosures have not been given.
16. The figures for previous year / period have been regrouped / rearranged wherever considered necessary.

**For LYKA LABS LIMITED**

*N. I. Gandhi*

N. I. Gandhi (DIN 00021530)  
(Chairman & Managing Director)

Mumbai  
29<sup>th</sup> May, 2018



*28*